Pensionfund Sabic Has $1.17 Million Stock Holdings in Cencora, Inc. (NYSE:COR)

Pensionfund Sabic lessened its position in shares of Cencora, Inc. (NYSE:COR) by 10.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,200 shares of the company’s stock after selling 600 shares during the quarter. Pensionfund Sabic’s holdings in Cencora were worth $1,170,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. Rise Advisors LLC acquired a new stake in shares of Cencora during the first quarter worth $25,000. New Millennium Group LLC acquired a new position in shares of Cencora during the 2nd quarter worth about $26,000. TCTC Holdings LLC bought a new position in shares of Cencora in the 1st quarter valued at about $29,000. TFO Wealth Partners LLC bought a new position in Cencora in the first quarter valued at approximately $30,000. Finally, MFA Wealth Advisors LLC bought a new position in shares of Cencora in the 2nd quarter valued at about $30,000. Institutional investors own 97.52% of the company’s stock.

Insiders Place Their Bets

In other Cencora news, CEO Steven H. Collis sold 10,755 shares of the business’s stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $222.12, for a total transaction of $2,388,900.60. Following the completion of the sale, the chief executive officer now owns 285,088 shares in the company, valued at approximately $63,323,746.56. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, CEO Steven H. Collis sold 10,755 shares of Cencora stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total transaction of $2,388,900.60. Following the sale, the chief executive officer now directly owns 285,088 shares in the company, valued at $63,323,746.56. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the transaction, the insider now owns 19,980,000 shares of the company’s stock, valued at approximately $4,806,388,800. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 4,450,399 shares of company stock worth $1,070,392,799. Corporate insiders own 15.80% of the company’s stock.

Cencora Trading Up 0.5 %

NYSE:COR opened at $222.20 on Friday. Cencora, Inc. has a 52 week low of $182.75 and a 52 week high of $247.66. The firm’s fifty day moving average is $233.47 and its 200-day moving average is $231.62. The firm has a market cap of $44.32 billion, a P/E ratio of 24.31, a P/E/G ratio of 1.58 and a beta of 0.44. The company has a debt-to-equity ratio of 3.93, a quick ratio of 0.55 and a current ratio of 0.89.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, topping analysts’ consensus estimates of $3.18 by $0.16. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The business had revenue of $74.20 billion during the quarter, compared to the consensus estimate of $73.32 billion. During the same period in the previous year, the company posted $2.92 earnings per share. The firm’s revenue for the quarter was up 10.8% on a year-over-year basis. Equities analysts expect that Cencora, Inc. will post 13.63 earnings per share for the current year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 9th were issued a $0.51 dividend. The ex-dividend date of this dividend was Friday, August 9th. This represents a $2.04 annualized dividend and a yield of 0.92%. Cencora’s payout ratio is currently 22.32%.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on COR. Robert W. Baird dropped their price target on Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a research note on Friday, September 6th. JPMorgan Chase & Co. increased their target price on shares of Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 21st. Leerink Partners dropped their target price on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research report on Monday. Wells Fargo & Company boosted their target price on Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 1st. Finally, Bank of America reiterated a “neutral” rating and issued a $245.00 price target (down from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $259.44.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.